Abstract
No public abstract is available from the verified source records.
J. Romaní
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa
2025
Two phase 3 trials of adalimumab for hidradenitis suppurativa
10.1056/nejmoa1504370 · 2016
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE)
10.1016/s0140-6736(23)00022-3 · 2023
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
No additional external references are available.